scholarly journals Erlotinib Treatment in a Case of Lung Adenocarcinoma Mimicking Interstitial Lung Disease

2017 ◽  
Vol 19 (1) ◽  
pp. 51-53
Author(s):  
Senay Yilmaz ◽  
Guntulu Ak ◽  
Muzaffer Metintas
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Adenocarcinoma ◽  
Lung Disease

scholarly journals Lung adenocarcinoma presenting as interstitial lung disease

2020 ◽  
Vol 13 (8) ◽  
pp. e235602
Author(s):  
Aditya Mehta ◽  
Anandbir Bath ◽  
Akshaya Gadre ◽  
Mark Schauer
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Adenocarcinoma ◽  
Lung Disease

Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma

2020 ◽  
Author(s):  
Luiza Lara Gadotti ◽  
Felipe Sales Nogueira Amorim Canedo ◽  
Maurício Fernando Silva Almeida Ribeiro ◽  
Karina Perez Sacardo ◽  
Rodrigo Saddi ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Adenocarcinoma ◽  
Lung Disease

Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease

2009 ◽  
Vol 65 (4) ◽  
pp. 803-806 ◽  
Author(s):  
Tomoya Fukui ◽  
Sakiko Otani ◽  
Ryuji Hataishi ◽  
Shi-Xu Jiang ◽  
Yasuto Nishii ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Adenocarcinoma ◽  
Lung Disease ◽  
Egfr Mutant

scholarly journals Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature

Lung Cancer ◽  
2012 ◽  
Vol 77 (2) ◽  
pp. 464-468 ◽  
Author(s):  
Yosuke Togashi ◽  
Katsuhiro Masago ◽  
Yasuhiro Hamatani ◽  
Yuichi Sakamori ◽  
Hiroki Nagai ◽  
...  
Keyword(s):  
Case Report ◽  
Interstitial Lung Disease ◽  
Lung Adenocarcinoma ◽  
Lung Disease ◽  
Leptomeningeal Metastases ◽  
Review Of The Literature

scholarly journals Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease

2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Tatsuya Nitawaki ◽  
Yoshihiko Sakata ◽  
Kodai Kawamura ◽  
Kazuya Ichikado
Keyword(s):  
Case Report ◽  
Interstitial Lung Disease ◽  
Lung Adenocarcinoma ◽  
Lung Disease ◽  
Drug Induced

scholarly journals Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in A Patient with Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report

2021 ◽  
pp. 100271
Author(s):  
Mizuha Haraguchi Hashiguchi ◽  
Takashi Sato ◽  
Hiroki Yamamoto ◽  
Rinako Watanabe ◽  
Junko Kagyo ◽  
...  
Keyword(s):  
Case Report ◽  
Interstitial Lung Disease ◽  
Lung Adenocarcinoma ◽  
Lung Disease

scholarly journals A Novel c-Mesenchymal-Epithelial Transition Factor Intergenic Fusion Response to Crizotinib in a Chinese Patient With Lung Adenocarcinoma: A Case Report

2021 ◽  
Vol 11 ◽  
Author(s):  
Hongge Liang ◽  
Dexun Zhou ◽  
Lin Dai ◽  
Moqin Zhang ◽  
Zhancheng Gao ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Adenocarcinoma ◽  
Lung Disease ◽  
Lower Lobe ◽  
Tyrosine Kinase Receptor ◽  
Carcinogenic Activity ◽  
First Case ◽  
Mesenchymal Epithelial Transition Factor ◽  
Factor C ◽  
Mesenchymal Epithelial Transition

BackgroundThe c-mesenchymal–epithelial transition factor (C-MET) is an oncogene encoding a tyrosine kinase receptor that plays an important role in tumor growth and metastasis. The National Comprehensive Cancer Network (NCCN) guidelines have approved carbatinib/crizotinib for advanced non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping.MethodsIn June 2020, the Department of Respiratory and Critical Care Medicine of Peking University People’s Hospital admitted a 72-year-old male patient with lung adenocarcinoma (LADC) with a history of interstitial lung disease secondary to antineutrophil cytoplasmic antibody-associated vasculitis. Genetic examination by next-generation sequencing showed an intergenic fusion of MET, and crizotinib was administered on August 14, 2020. Follow-up showed that tumor volume was significantly reduced. However, crizotinib was discontinued in November 2020 because of the patient’s worsening interstitial lung disease, and CT scans showed continued partial response (PR) for 5 months. In April 2021, right lower lobe mass progressed, and disease progression was considered.ConclusionThis was the first case of a patient with LADC with MET intergenic fusion who significantly benefited from crizotinib. Even after crizotinib was discontinued for 5 months, the patient continued exhibiting PR, suggesting that MET intergenic fusion may have carcinogenic activity in LADC and was sensitive to crizotinib.

Successful treatment with brigatinib in a patient with ALK -rearranged lung adenocarcinoma who developed crizotinib-induced interstitial lung disease

Lung Cancer ◽  
2018 ◽  
Vol 119 ◽  
pp. 99-102 ◽  
Author(s):  
Marta Doménech ◽  
Maria Jové ◽  
Samantha Aso ◽  
Mar Marín ◽  
Ernest Nadal
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Adenocarcinoma ◽  
Lung Disease ◽  
Successful Treatment
Sign in / Sign up

Export Citation Format

Share Document